In:
International Journal of Cancer, Wiley, Vol. 139, No. 9 ( 2016-11), p. 2106-2115
Abstract:
What's New? For patients with acute lymphoblastic leukemia (ALL), blood‐forming stem cells can be an effective therapy. In this study, the authors asked whether children for whom a matching donor cannot be found might benefit from either haploidentical hematopoietic stem cell transplantation (haplo‐HSCT) or umbilical cord‐blood transplantation (UCBT). They found that both therapies improved two‐year survival, although restoration of mature white blood cells was significantly faster after haplo‐HSCT than after UCBT. These therapeutic strategies may thus increase the donor pool for high‐risk children with ALL.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2016
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8